Dr Reddy's Cancer Drug Approved in South Africa

Dr Reddy's Laboratories, through its South African subsidiary, has successfully registered a new PD-1 inhibitor. This advanced treatment is intended for patients battling recurrent or metastatic nasopharyngeal carcinoma, a particularly aggressive form of head and neck cancer. The medication functions by inhibiting the PD-1 protein on immune T cells, thereby preventing it from binding to PD-L1 on cancer cells. This action effectively removes the natural restraints on the immune system, enabling T cells to more effectively identify and attack cancerous tumors.

This development represents a significant step in enhancing access to cutting-edge oncology care, particularly for patients in underserved communities. Dr Rashem Mothilal, General Manager of Dr Reddy's Laboratories South Africa, emphasized the company's dedication to providing innovative treatments for all cancer patients, regardless of the rarity of their diagnosis. Nasopharyngeal carcinoma originates behind the nose and above the throat, with early symptoms like persistent nasal congestion and hearing loss potentially delaying diagnosis until the disease has progressed.